SAN FRANCISCO, Oct. 5, 2017 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company
focused on saving and improving the lives of pets, today announced
that Denise Bevers, Co-Founder and
Chief Operating Officer, will participate in the Oppenheimer &
Co. Specialty Pharmaceuticals Conference, being held on
October 11, 2017 in New York City. The event will feature
one-on-one meetings at which investors will have the opportunity to
meet with management to discuss key therapeutic programs in
development and upcoming milestones.
About Kindred Biosciences
Kindred Biosciences is a pre-commercialization stage
biopharmaceutical company focused on saving and improving the lives
of pets. Its mission is to bring to pets the same kinds of safe and
effective medicines that human family members enjoy. The Company's
strategy is to identify compounds and targets that have already
demonstrated safety and efficacy in humans and to develop
therapeutics based on these validated compounds and targets for
dogs, cats and horses. The Company has a deep pipeline of novel
drugs and biologics in development across many therapeutic
classes.
For more information or to download the corporate presentation,
visit www.KindredBio.com/LearnMore. Stay connected with KindredBio
on Facebook at www.Facebook.com/KindredBio.
Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904
View original content with
multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-participate-in-the-oppenheimer--co-specialty-pharmaceuticals-conference-300532013.html
SOURCE Kindred Biosciences, Inc.